Form4insider filings, from the source

SEC Form 4 · accession 0001140361-17-044229

Loxo Oncology, Inc. · LOXO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Joshua H. Bilenker
Officer — President & CEO · Director
Period of report
Nov 27, 2017
Accepted (ET)
Nov 29, 2017 · 5:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockNov 20, 2017G6,000$0.00D182,707D
Common StockNov 27, 2017M7,500$1.184A190,207D
Common StockF2,F3Nov 27, 2017S4,693$74.1302D185,514D
Common StockF2,F4Nov 27, 2017S1,601$74.9838D183,913D
Common StockF2,F5Nov 27, 2017S906$76.1989D183,007D
Common StockF2,F6Nov 27, 2017S300$77.0733D182,707D
Common StockNov 28, 2017M7,500$1.184A190,207D
Common StockF2,F7Nov 28, 2017S2,400$73.1513D187,807D
Common StockF2,F8Nov 28, 2017S2,460$73.9936D185,347D
Common StockF2,F9Nov 28, 2017S1,850$75.2095D183,497D
Common StockF2,F10Nov 28, 2017S790$75.8524D182,707D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (right to buy)F11$1.184Nov 27, 2017M7,500D—Nov 14, 2023Common Stock7,500112,190D
Employee Stock Option (right to buy)F11$1.184Nov 28, 2017M7,500D—Nov 14, 2023Common Stock7,500104,690D

Explanation of responses